Independent reference. Not affiliated with, endorsed by, or speaking for the U.S. Food and Drug Administration.
FDA Medication Tracker

← All approvals · Weight loss & diabetes · 2025

Redemplo (plozasiran)

The FDA approved Redemplo (plozasiran) on November 18, 2025 to reduce triglycerides in adults with familial chylomicronemia syndrome.
Brand name
Redemplo
Generic name
plozasiran
FDA approval date
November 18, 2025
Approved use (FDA wording)
To reduce triglycerides in adults with familial chylomicronemia syndrome
Company
Arrowhead
Application
NDA219947
Dosage form / route
SOLUTION · SUBCUTANEOUS
Drug class (EPC)
APOC-III-directed RNA Interaction [EPC]
Boxed warning on label
Not listed
Category on this site
Weight loss & diabetes

Indications and usage, from the FDA label

REDEMPLO is indicated as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS). REDEMPLO is an apolipoprotein C-III ( apoC-III )-directed small interfering ribonucleic acid (siRNA) indicated as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS). ( 1 )

Official sources

Facts only. This site lists what the FDA has approved and what the FDA says each drug is approved for, quoted or closely paraphrased from FDA and openFDA records. It gives no medical advice, no dosing, and no comparisons, and it says nothing about whether a drug is right for anyone. Talk to a licensed clinician about any medication. Records can lag or contain errors; the FDA's own pages are authoritative.